Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
Sentara Cardiovascular Research Institute
mi
from
Norfolk, VA
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
Sentara Cardiovascular Research Institute
mi
from
Norfolk, VA
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
CVAL
mi
from
Virginia Beach, VA
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
CVAL
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
Hope Heart Institute
mi
from
Kirkland, WA
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
Hope Heart Institute
mi
from
Kirkland, WA
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
University of Washington
mi
from
Seattle, WA
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
CAMC Health Education and Research Institute
mi
from
Charleston, WV
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
CAMC Health Education and Research Institute
mi
from
Charleston, WV
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
University Cardiovascular Services
mi
from
Huntington, WV
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
University Cardiovascular Services
mi
from
Huntington, WV
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
William S. Middleton Memorial VA Hospital
mi
from
Madison, WI
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
William S. Middleton Memorial VA Hospital
mi
from
Madison, WI
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
University of Wisconsin-Madison
mi
from
Madison, WI
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated:  10/6/2009
CaRE Foundation, Inc
mi
from
Wausau, WI
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
Status: Enrolling
Updated: 10/6/2009
CaRE Foundation, Inc
mi
from
Wausau, WI
Click here to add this to my saved trials
Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients
Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients
Status: Enrolling
Updated:  10/26/2009
University of Iowa
mi
from
Iowa City, IA
Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients
Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients
Status: Enrolling
Updated: 10/26/2009
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Treatment of Claudication With a Peristaltic Pulse Pneumatic Device
Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication
Status: Enrolling
Updated:  11/3/2009
White River Junction VAMC
mi
from
White River Junction, VT
Treatment of Claudication With a Peristaltic Pulse Pneumatic Device
Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication
Status: Enrolling
Updated: 11/3/2009
White River Junction VAMC
mi
from
White River Junction, VT
Click here to add this to my saved trials
Effects of Age and Exercise on Blood Pressure Regulation
Arterial Stiffness With Age: Part 1 and 2
Status: Enrolling
Updated:  12/10/2009
Spaulding Rehabilitation Hospital
mi
from
Boston, MA
Effects of Age and Exercise on Blood Pressure Regulation
Arterial Stiffness With Age: Part 1 and 2
Status: Enrolling
Updated: 12/10/2009
Spaulding Rehabilitation Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Status: Enrolling
Updated:  12/16/2009
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Status: Enrolling
Updated: 12/16/2009
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Status: Enrolling
Updated:  12/16/2009
Peripheral Vascular Associates
mi
from
San Antonio, TX
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
Status: Enrolling
Updated: 12/16/2009
Peripheral Vascular Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Mayo Clinic Hospital, Arizona
mi
from
Phoenix, AZ
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Mayo Clinic Hospital, Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Loma Linda University School of Medicine
mi
from
Loma Linda, CA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Loma Linda University School of Medicine
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Santa Monica - UCLA Medical Center
mi
from
Los Angeles, CA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Santa Monica - UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
UCLA Medical Center
mi
from
Los Angeles, CA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
The Neurology Center: Tri-City Medical Center
mi
from
Oceanside, CA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
The Neurology Center: Tri-City Medical Center
mi
from
Oceanside, CA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Shasta Regional Medical
mi
from
Redding, CA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Shasta Regional Medical
mi
from
Redding, CA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Bridgeport Hospital
mi
from
Bridgeport, CT
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Bridgeport Hospital
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Neurologic Consultants, PA
mi
from
Fort Lauderdale, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Neurologic Consultants, PA
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Shands Jacksonville / University of Florida
mi
from
Jacksonville, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Shands Jacksonville / University of Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
OCALA Neurodiagnostic Center
mi
from
Ocala, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
OCALA Neurodiagnostic Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Florida Hospital Neuroloscience Institute
mi
from
Orlando, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Florida Hospital Neuroloscience Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Fawcett Memorial Hospital
mi
from
Port Charlotte, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Fawcett Memorial Hospital
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Peace River Regional Medical Center
mi
from
Port Charlotte, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Peace River Regional Medical Center
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Tallahassee Memorial Healthcare
mi
from
Tallahassee, FL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Tallahassee Memorial Healthcare
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
The Queens Medical Center, Neuroscience Institute
mi
from
Honolulu, HI
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
The Queens Medical Center, Neuroscience Institute
mi
from
Honolulu, HI
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Mercy Hospital
mi
from
Chicago, IL
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Mercy Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Elkhart Clinic, LLC - Neurology
mi
from
Elkhart, IN
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Elkhart Clinic, LLC - Neurology
mi
from
Elkhart, IN
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Parkview Research Center
mi
from
Fort Wayne, IN
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Baystate Medical Center
mi
from
Springfield, MA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Wayne State University
mi
from
Detroit, MI
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
St. Mary's Duluth Clinic
mi
from
Duluth, MN
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
St. Mary's Duluth Clinic
mi
from
Duluth, MN
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Deaconess Billings Clinical Research Center
mi
from
Billings, MT
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Deaconess Billings Clinical Research Center
mi
from
Billings, MT
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
NJ Neuroscience Institute
mi
from
Edison, NJ
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
NJ Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Neurology Consultants of Burlington County
mi
from
Lumberton, NJ
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Neurology Consultants of Burlington County
mi
from
Lumberton, NJ
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Neurology Group of Bergen County
mi
from
Ridgewood, NJ
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Neurology Group of Bergen County
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Shore Neurology
mi
from
Toms River, NJ
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Shore Neurology
mi
from
Toms River, NJ
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Kaleida Stroke Center
mi
from
Buffalo, NY
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Kaleida Stroke Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
United Health Services Hospitals
mi
from
Johnson City, NY
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
United Health Services Hospitals
mi
from
Johnson City, NY
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Winthrop University Hospital
mi
from
Minneola, NY
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Winthrop University Hospital
mi
from
Minneola, NY
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Weill Medical College of Cornell University
mi
from
New York, NY
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials